Yusuke Moritoh

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 11

Top Venues

Clinical pharmacology and therapeutics

Diabetes, obesity & metabolism

The Journal of pharmacology and experimental therapeutics

Diabetes

SCOHIA PHARMA, Inc.

This page only lists publications with an associated author ORCID identifier.

Affiliation History

SCOHIA PHARMA, Inc.

Japan

Biology Head/Director :: Research and Development Division

Publications

Harunobu Nishizaki, Tomoya Kagawa, Jun Sugama, Akihiro Kobayashi, Yusuke Moritoh, Masanori Watanabe
Oral SSTR5 Antagonist SCO-240 for Growth Hormone Stimulation: A Phase I Single-Dose Study in Healthy Individuals. Clinical pharmacology and therapeutics 115 (6) (2024)
Harunobu Nishizaki, Tomoya Kagawa, Jun Sugama, Akihiro Kobayashi, Yusuke Moritoh, Masanori Watanabe
Oral SSTR5 Antagonist SCO-240 for Growth Hormone Stimulation: A Phase I Single-Dose Study in Healthy Individuals. Clinical pharmacology and therapeutics (2024)
Harunobu Nishizaki, Tomoya Kagawa, Jun Sugama, Akihiro Kobayashi, Yusuke Moritoh, Masanori Watanabe
Oral SSTR5 Antagonist SCO-240 for Growth Hormone Stimulation: A Phase I Single-Dose Study in Healthy Individuals. Clinical pharmacology and therapeutics 115 (6) (2024)
Ryokichi Koyama, Mitsugi Ookawara, Masanori Watanabe, Yusuke Moritoh
Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats. Molecular pharmacology 99 (4) (2021)
Yusuke Moritoh, Shin-Ichi Abe, Hiroki Akiyama, Akihiro Kobayashi, Ryokichi Koyama, Ryoma Hara, Shizuo Kasai, Masanori Watanabe
The enzymatic activity of inositol hexakisphosphate kinase controls circulating phosphate in mammals. Nature communications 12 (1) (2021)
Harunobu Nishizaki, Osamu Matsuoka, Tomoya Kagawa, Akihiro Kobayashi, Masanori Watanabe, Yusuke Moritoh
SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans. Diabetes 70 (10) (2021)
Mitsugi Ookawara, Keisuke Matsuda, Masanori Watanabe, Yusuke Moritoh
The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight. The Journal of pharmacology and experimental therapeutics 375 (1) (2020)
Jun Sugama, Yuko Katayama, Yusuke Moritoh, Masanori Watanabe
Enteropeptidase inhibition improves kidney function in a rat model of diabetic kidney disease. Diabetes, obesity & metabolism 23 (1) (2020)
Hikaru Ueno, Ryo Ito, Shin-Ichi Abe, Mitsugi Ookawara, Hirohisa Miyashita, Hitomi Ogino, Yasufumi Miyamoto, Tomoki Yoshihara, Akihiro Kobayashi, Yoshiyuki Tsujihata, Koji Takeuchi, Masanori Watanabe, Yukio Yamada, Tsuyoshi Maekawa, Nobuhiro Nishigaki, Yusuke Moritoh
SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity. The Journal of pharmacology and experimental therapeutics 370 (2) (2019)
Hiroaki Yashiro, Kenichi Hamagami, Hideyuki Hiyoshi, Jun Sugama, Kazue Tsuchimori, Fuminari Yamaguchi, Yusuke Moritoh, Minoru Sasaki, Tsuyoshi Maekawa, Yukio Yamada, Masanori Watanabe
SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice. Diabetes, obesity & metabolism 21 (10) (2019)
Masako Sasaki, Ikuo Miyahisa, Sachiko Itono, Hiroaki Yashiro, Hideyuki Hiyoshi, Kazue Tsuchimori, Ken-Ichi Hamagami, Yusuke Moritoh, Masanori Watanabe, Kimio Tohyama, Minoru Sasaki, Jun-Ichi Sakamoto, Tomohiro Kawamoto
Discovery and characterization of a small-molecule enteropeptidase inhibitor, SCO-792. Pharmacology research & perspectives 7 (5) (2019)

Yusuke Moritoh.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yusuke Moritoh